RxDoctor Payments DataLook up a doctor →

Rainer Vogel, MD

Pain Medicine · Henderson, NVNPI 1396727756

Payments from drug & device makers

$349,095in general payments, 2019–2025

Across 808 payments — averaging $432.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$155K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86K
  • Boston Scientific$29K
  • Nevro Corp.$24K
  • Pacira Therapeutics, Inc.$19K
  • Aurora Spine, Inc.$17K
  • plus $18K from 50 others
$1,800in research payments, 2019–2025

Across 2 payments — averaging $900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nevro Corp.$2K

What the payments were for

  • Consulting fees$19,2158%
  • Speaking & faculty fees$161,08770%
  • Travel & lodging$26,39011%
  • Food & beverage$23,43510%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349,095 in reported general payments places this provider in the 95th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$270,516
Medicare patients
233
Services billed
12,705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen756$30,463
MovantikNaloxegol Oxalate49$19,952
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen546$17,585
BotoxOnabotulinumtoxina11$14,293
Oxycodone Hcl479$10,610
Duloxetine Hcl715$10,453
Gabapentin762$10,016
Diclofenac Sodium533$9,187
Aimovig AutoinjectorErenumab-Aooe11$8,309
Fentanyl58$4,437
Tizanidine Hcl490$3,731
Morphine Sulfate102$3,635
Morphine Sulfate ErMorphine Sulfate175$3,564
Pregabalin143$3,434
Buprenorphine24$3,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$169$19,95249 claims
AbbVieBotox$134$14,29311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 pain medicine providers in Nevada.

Other pain medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →